PT-141, also called bremelanotide, is a peptide that works through melanocortin pathways in the brain involved in sexual desire and arousal. The FDA-approved version, VYLEESI, is approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder, or HSDD, when low desire causes distress or relationship difficulty and is not due to another medical, mental health, medication, substance, or relationship
cause.
